The estimated Net Worth of Jeffrey Robert Ajer is at least $22.1 Milion dollars as of 2 May 2024. Mr Ajer owns over 5,000 units of Biomarin Pharmaceutical stock worth over $5,660,506 and over the last 12 years he sold BMRN stock worth over $15,347,605. In addition, he makes $1,051,257 as Exec. VP & Chief Commercial Officer at Biomarin Pharmaceutical.
Mr has made over 74 trades of the Biomarin Pharmaceutical stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of BMRN stock worth $414,550 on 2 May 2024.
The largest trade he's ever made was exercising 49,000 units of Biomarin Pharmaceutical stock on 25 January 2023 worth over $3,322,690. On average, Mr trades about 2,644 units every 34 days since 2012. As of 2 May 2024 he still owns at least 66,767 units of Biomarin Pharmaceutical stock.
You can see the complete history of Mr Ajer stock trades at the bottom of the page.
Jeffrey Robert Ajer is the Exec. VP & Chief Commercial Officer at Biomarin Pharmaceutical.
As the Exec. VP & Chief Commercial Officer of Biomarin Pharmaceutical, the total compensation of Mr Ajer at Biomarin Pharmaceutical is $1,051,257. There are 7 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of $18,405,900.
Mr Ajer is 59, he's been the Exec. VP & Chief Commercial Officer of Biomarin Pharmaceutical since . There are 13 older and 8 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy oraz Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: